Benefits
Improved Blood Flow
A meta-analysis of 11 randomized trials in 387 adults taking 4 to 24 grams a day found oral L-arginine lowered systolic blood pressure by about 5.4 mmHg and diastolic by about 2.7 mmHg compared with placebo. A separate meta-analysis of 13 trials found it improved blood vessel flexibility only in people whose vessel function was already low at the start, and not in people whose function was normal. No study cited here involves peripheral artery disease or exercise capacity, and high blood pressure is a medical condition that needs a doctor.
Heart Health
The cited evidence covers only modest blood pressure and blood vessel function changes; no study cited here looked at angina or at preventing heart disease. Safety matters more here than benefit: in a randomized trial in 153 people recovering from a heart attack, 9 grams a day of L-arginine did not improve heart function, and 6 people in the arginine group died compared with none on placebo, which ended the trial early.
Erectile Dysfunction
In a meta-analysis of 4 randomized trials in 373 men with erectile dysfunction, L-arginine improved erectile function scores, and adding it to prescription PDE5 inhibitors gave extra benefit. Those prescription drugs on their own worked better than L-arginine on its own. No pycnogenol combination study is cited on this page, and erectile dysfunction can be an early sign of a circulatory problem, so it is worth seeing a doctor rather than self-treating.
Exercise Performance
None of the four meta-analyses cited on this page examined exercise performance, so there is no citation here supporting an athletic benefit. L-arginine is a popular pre-workout ingredient, but its performance evidence is weak, and much of an oral dose is broken down in the gut and liver before it reaches the blood, which is why many products use L-citrulline instead.
Wound Healing
No wound healing study is cited on this page. Arginine appears in some hospital nutrition formulas used for burn and surgical patients, but that is supervised medical nutrition, not evidence for taking an arginine supplement at home.
Immune Support
Immune cells use arginine to make nitric oxide, but no immune outcome study is cited on this page, so treat this as background biology rather than a demonstrated benefit of taking a supplement.
Mechanism of action
Nitric Oxide Synthesis
L-arginine is converted into nitric oxide by the enzyme nitric oxide synthase (NOS) in endothelial cells, macrophages, and other tissues. This reaction also produces L-citrulline as a byproduct. Nitric oxide acts as a vasodilator, relaxing smooth muscle cells in blood vessel walls, which improves blood flow and reduces vascular resistance.
Vascular Effects
By increasing nitric oxide levels, L-arginine can relax blood vessels, which is the proposed reason for the small blood pressure changes measured in trials. Notably, the pooled trials found improved blood vessel function only in people whose function was already impaired, which fits the idea that there is less to gain when nitric oxide production is already normal. Improved oxygen delivery to tissues has not been shown in the studies cited here.
Cellular and Metabolic Role
L-arginine supports protein synthesis and serves as a building block for proteins, aiding tissue repair and growth. Arginine given by injection is used in hospitals as a test that triggers growth hormone release, but ordinary oral doses have not been shown in any study cited here to change metabolism or speed up recovery. In immune cells, L-arginine supports the production of NO, which has antimicrobial properties and modulates immune responses.
Clinical trials
Randomized, double-blind, placebo-controlled trial in 101 patients with severe COVID-19 receiving L-arginine 1.66 g twice daily plus standard therapy vs standard therapy alone. (Fiorentino et al. 2021, EClinicalMedicine)
101 severe COVID-19 patients.
In hospitalized patients with severe COVID-19, the L-arginine group needed breathing support for less time and left hospital sooner than the control group. This study is not in this page's reference list, it was run in seriously ill hospitalized patients who were also receiving standard medical treatment, and it says nothing about taking arginine as a supplement when you are well.
Double-blind, randomized, placebo-controlled trial in 98 patients (51 L-arginine 6 g/day, 47 placebo) with vasculogenic erectile dysfunction for 3 months. (2021)
98 men with vasculogenic ED.
L-arginine modestly improved erectile function scores (IIEF-5) compared with placebo in men diagnosed with a blood-flow-related form of erectile dysfunction. This individual trial is not in this page's reference list, although a meta-analysis covering this area is cited. Critical context: PDE5 inhibitors (sildenafil, tadalafil) remain first-line for ED; arginine effects are smaller in magnitude; arginine may have niche role for mild ED or as adjunct in patients on standard therapy. L-citrulline produces higher arginine levels than equivalent doses of L-arginine itself (better oral bioavailability).
Double-blind, randomized, placebo-controlled trial in 56 healthy male athletes in Iran aged 16-35 receiving L-arginine vs placebo. Outcomes: cardiovascular risk factors, exercise performance.
56 healthy male athletes.
The write-up reports modest changes in some cardiovascular risk markers in 56 healthy male athletes. This trial is not in this page's reference list, and none of the cited meta-analyses cover exercise performance, so it should not be read as evidence that L-arginine improves athletic results.
Prospective, open-label, single-arm trial in 20 amyotrophic lateral sclerosis (ALS) patients (40% female, mean age 60.5). Outcomes: ALSFRS-R, FVC, biomarkers.
20 ALS patients (single-arm, no placebo).
The report describes modest signs of stability, but there was no placebo group, everyone knew they were taking arginine, and only 20 people took part. That is the weakest study design there is and it cannot show that a treatment works. This study is also not in this page's reference list, and ALS is a fatal neurological disease. ALS treatment landscape includes riluzole, edaravone (and now tofersen for SOD1-ALS) — supplemental arginine has no role in evidence-based ALS care.
Meta-analysis of 22 randomized, placebo-controlled trials (30 effect sizes) examining oral L-arginine effects on blood pressure. (2022)
Pooled across 22 RCTs.
L-arginine lowered systolic blood pressure by about 5.4 mmHg and diastolic by about 2.7 mmHg compared with placebo. Those are the same figures reported by the meta-analysis this page actually cites (Dong 2011, 11 trials, 387 adults, 4 to 24 grams a day), so the pooled blood pressure numbers are the dependable part of this card rather than the trial count given above. Mechanism via NO-mediated vasodilation. Note: should not replace antihypertensive medications in established hypertension — adjunctive only.
Multicenter, randomized, double-blind, placebo-controlled trial (Vascular Interaction with Age in Myocardial Infarction — VINTAGE MI) in 153 post-STEMI patients receiving L-arginine 9 g/day vs placebo for 6 months. (Schulman et al. 2006, JAMA)
153 post-STEMI patients. 6-month intervention.
Primary endpoint negative: L-arginine did not improve vascular stiffness or LV ejection fraction vs placebo. Critical safety concern: L-arginine group had 6 deaths vs 0 in placebo group — an alarming and statistically significant signal that led to trial termination for harm. This is a major negative trial that has shaped clinical thinking — high-dose L-arginine should not be used in post-MI patients.
Randomized, double-blind, placebo-controlled crossover trial in 15 patients with moderate to severe heart failure receiving 5.6-12.6 g/day L-arginine vs placebo. (Bednarz et al. 2000, Int J Cardiol)
15 heart failure patients (small).
In 15 people with moderate to severe heart failure, L-arginine modestly improved exercise tolerance and forearm blood vessel widening compared with placebo. Fifteen people is a very small study, it dates from 2000, and it is not in this page's reference list. Given the deaths seen in the post-heart-attack trial, L-arginine is not part of standard heart failure care. Modern HF therapy (ACEi/ARB/ARNI, beta-blocker, MRA, SGLT2i) has clear mortality evidence.